EcoDrugPlus

Somatostatin Receptor 2

Ensembl ID : ENSSTUG00000043807
Gene Symbol: SSTR2
3 Cross references
188 Possible Orthologues:

Somatostatin Receptor Type 5-Like

Ensembl ID : ENSSTUG00000004456
Gene Symbol: LOC115171461
2 Cross references
186 Possible Orthologues:

Somatostatin Receptor Type 5-Like

Ensembl ID : ENSSTUG00000035957
Gene Symbol: LOC115147881
2 Cross references
181 Possible Orthologues:

Somatostatin Receptor Type 5-Like

Ensembl ID : ENSSTUG00000017847
Gene Symbol: LOC115202902
2 Cross references
179 Possible Orthologues:

Somatostatin Receptor Type 5-Like

Ensembl ID : ENSSTUG00000030999
Gene Symbol: LOC115177915
2 Cross references
179 Possible Orthologues:

Sphingosine 1-Phosphate Receptor 1

Ensembl ID : ENSSTUG00000017507
Gene Symbol: LOC115158060
3 Cross references
194 Possible Orthologues:

Sphingosine 1-Phosphate Receptor 1-Like

Ensembl ID : ENSSTUG00000044999
Gene Symbol: LOC115151622
3 Cross references
194 Possible Orthologues:

Sphingosine Kinase 2-Like

Ensembl ID : ENSSTUG00000037608
Gene Symbol: LOC115176532
2 Cross references
194 Possible Orthologues:

Sphingosine Kinase 2-Like

Ensembl ID : ENSSTUG00000000827
Gene Symbol: LOC115189202
2 Cross references
192 Possible Orthologues:

Spleen Associated Tyrosine Kinase

Ensembl ID : ENSSTUG00000025230
Gene Symbol: SYK
3 Cross references
200 Possible Orthologues:

Steroid 17-Alpha-Hydroxylase/17,20 Lyase

Ensembl ID : ENSSTUG00000007509
Gene Symbol: LOC115193858
3 Cross references
210 Possible Orthologues:

Sterol O-Acyltransferase 1-Like

Ensembl ID : ENSSTUG00000046529
Gene Symbol: LOC115158397
3 Cross references
210 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).